ArticleJournal of eating disorders2025
Coordinated epigenetic dysregulation of CNR1 and FAAH genes drives endocannabinoid system dysfunction in anorexia nervosa.
Article in Journal of eating disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Endocannabinoid System in Neuropsychiatric Disorders: Mechanisms, Dysregulation and Therapeutic Potential.Biomedicines · 2026Review
- Dysregulation of neurodevelopmental regulatory networks in Anorexia Nervosa: an integrated multi-layered omics analysis.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAnorexia nervosa (AN) is a severe psychiatric disorder with limited biomarkers for diagnosis and treatment monitoring. We investigated endocannabinoid system (ECS) dysregulation in AN through integrated epigenetic and genetic analysis of saliva.
methodsWe analyzed DNA methylation patterns of cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes, characterized genetic polymorphisms, and quantified expression of exosomal microRNAs targeting these genes in AN patients versus healthy controls.
resultsWe discovered a novel bidirectional epigenetic dysregulation of the ECS: CNR1 promoter hypermethylation coupled with FAAH promoter hypomethylation. This dual-target mechanism systematically impairs endocannabinoid signaling by simultaneously reducing receptor availability while increasing endocannabinoid degradation. Compensatory miRNA responses (upregulated miR-342-3p, miR-23b-3p targeting CNR1; upregulated miR-4505, miR-1275 targeting FAAH) revealed dynamic regulatory attempts to counterbalance these primary epigenetic changes. This convergent pathway dysfunction demonstrates how multiple molecular mechanisms work in concert to dysregulate appetite regulation in AN. Combined biomarker panels showed superior diagnostic precision compared to individual markers.
conclusionsOur findings establish this bidirectional epigenetic dysregulation as a central mechanism underlying ECS dysfunction in AN, providing mechanistic insights that identify novel therapeutic targets and advance precision medicine approaches for this challenging disorder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.